PMV Pharmaceuticals published Phase I results for rezatapopt, a small molecule p53 reactivator selective for the TP53 Y220C mutation, reporting objective responses across multiple tumor types in heavily pretreated patients. The New England Journal of Medicine article described safety consistent with dose escalation and biomarker data supporting selective binding to the Y220C pocket. PMV said these data validate p53 reactivation as a therapeutic strategy and underpin registrational plans in platinum‑resistant ovarian cancer.